Duque denies receiving letter from Sinopharm regarding request for clinical trials By LLANESCA T. PANTI, GMA News
Published January 1, 2021 1:54pm Health Secretary Francisco Duque III on Friday denied that he did not act on a request of Chinese firm Sinopharm to conduct clinical trials for its COVID-19 vaccine in the Philippines. Interviewed on Super Radyo dzBB, Duque said he is not aware of any letter supposedly sent by Sinopharm in May 2020 requesting authorization to conduct clinical trials. “Wala akong alam [na sulat na nakarating sa akin]. Ang alam ko lang na nag-apply for Phase 3 clinical trials iyong Janssen, sa Johnson and Johnson ‘yun,” Duque said.
SunStar
+ January 01, 2021 FORTY-NINE fireworks-related injuries and one stray bullet incident have been reported as the Philippines welcomed 2021 amid the firecracker ban implemented by different local government units (LGUs).
In a press conference, Health Secretary Francisco Duque III said there have been a total of 50 revelry-related injuries from December 21, 2020 to January 1, 2021. This is 85 percent lower than the 340 total cases reported last year, said Duque.
“The lower numbers we achieved this year is a welcome development. But we will not stop until we achieve zero firework-related injuries,” he added.
The National Capital Region (NCR) reported the highest number with 22 cases, followed by Calabarzon (five cases), and Ilocos Region, Bicol Region, and Western Visayas (four cases each).
The EcoWaste Coalition expressed elation over the reduced number of firecracker-related injuries and fire incidents in Metro Manila during the New Year's Eve celebrations.
The Department of Health says it will investigate reports of unauthorized COVID-19 vaccinations, adding that doctors and other medical professionals administering illegal doses will be stripped of their medical license.
DOH: Docs administering vaccines, drugs sans FDA approval may lose license inquirer.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from inquirer.net Daily Mail and Mail on Sunday newspapers.